242 related articles for article (PubMed ID: 23375388)
1. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
2. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
Valentino MA; Lin JE; Snook AE; Li P; Kim GW; Marszalowicz G; Magee MS; Hyslop T; Schulz S; Waldman SA
J Clin Invest; 2011 Sep; 121(9):3578-88. PubMed ID: 21865642
[TBL] [Abstract][Full Text] [Related]
3. Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity.
Kim GW; Lin JE; Snook AE; Aing AS; Merlino DJ; Li P; Waldman SA
Nutr Diabetes; 2016 May; 6(5):e211. PubMed ID: 27214655
[TBL] [Abstract][Full Text] [Related]
4. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
5. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
6. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
Blomain ES; Merlino DJ; Pattison AM; Snook AE; Waldman SA
Mol Pharmacol; 2016 Sep; 90(3):199-204. PubMed ID: 27251363
[TBL] [Abstract][Full Text] [Related]
7. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
8. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
9. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
[TBL] [Abstract][Full Text] [Related]
10. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
[TBL] [Abstract][Full Text] [Related]
11. Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C.
Romi H; Cohen I; Landau D; Alkrinawi S; Yerushalmi B; Hershkovitz R; Newman-Heiman N; Cutting GR; Ofir R; Sivan S; Birk OS
Am J Hum Genet; 2012 May; 90(5):893-9. PubMed ID: 22521417
[TBL] [Abstract][Full Text] [Related]
12. Uroguanylin: how the gut got another satiety hormone.
Seeley RJ; Tschöp MH
J Clin Invest; 2011 Sep; 121(9):3384-6. PubMed ID: 21865649
[TBL] [Abstract][Full Text] [Related]
13. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
14. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
Marszalowicz GP; Snook AE; Magee MS; Merlino D; Berman-Booty LD; Waldman SA
Oncotarget; 2014 Oct; 5(19):9460-71. PubMed ID: 25294806
[TBL] [Abstract][Full Text] [Related]
15. Intestinal cell proliferation and senescence are regulated by receptor guanylyl cyclase C and p21.
Basu N; Saha S; Khan I; Ramachandra SG; Visweswariah SS
J Biol Chem; 2014 Jan; 289(1):581-93. PubMed ID: 24217248
[TBL] [Abstract][Full Text] [Related]
16. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
[TBL] [Abstract][Full Text] [Related]
17. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
[TBL] [Abstract][Full Text] [Related]
18. GUCY2C ligand replacement to prevent colorectal cancer.
Blomain ES; Pattison AM; Waldman SA
Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
[TBL] [Abstract][Full Text] [Related]
19. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer.
Waldman SA; Hyslop T; Schulz S; Barkun A; Nielsen K; Haaf J; Bonaccorso C; Li Y; Weinberg DS
JAMA; 2009 Feb; 301(7):745-52. PubMed ID: 19224751
[TBL] [Abstract][Full Text] [Related]
20. Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis.
Li P; Waldman SA
Cancer Biol Ther; 2010 Aug; 10(3):211-8. PubMed ID: 20592492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
